Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 2Phase EARLY_PHASE1 1Phase 4 1Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 4Tumor-Agnostic 2Plasma cell 2Lymphoid 2Head & Neck 2Breast 2Thoracic 1Other hematologic neoplasm 1NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 1

Interventions

gallium Ga 68 dotatate 690Y-octreotide, DOTA-Tyr(3)- 3Single Photon Emission Computed Tomography Computed Tomography 2Magnetic Resonance Spectroscopy 23-Iodobenzylguanidine 2lutetium Lu 177 dotatate 1lanreotide 1Tomography, X-Ray Computed 1Tomography, Emission-Computed, Single-Photon 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1Metformin 1Iodine-123 1Ga(III)-DOTATOC 168Ga-pentixafor 168Ga-FAPI 164Cu-SARTATE 13-fluorobenzylguanidine 1177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Positron Emission Tomography Computed Tomography × NET × Clear all
NCT04510311 2025-01-10

Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors

University of Michigan Rogel Cancer Center

Phase EARLY_PHASE1 Completed
32 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡